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Background andAims: Vitamin and iron deficiencies are common in patients with inflammatory bowel disease (IBD) as a result of chronic 
intestinal inflammation, increase in demand, or dietary restrictions. Here, we assessed the frequency of complications in relation to deficiency of 
iron, folate acid, and vitamin B12 in patients enrolled in the nationwide Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS).
Methods: A total of 2666 patients were included in the study, 1558 with Crohn’s disease (CD) and 1108 with ulcerative colitis (UC).
Results: Iron deficiency anemia was detected in 19.6% of CD patients and 21.6% of UC patients. In CD patients low BMI and nonsmoker status 
were positively associated with anemia. In both CD and UC, malabsorption syndrome, defined as failure of the GI tract to absorb 1 or more 
substances from the diet, was found to be significantly associated with anemia (6.2% and 3.8%, respectively) and current steroid use (40% CD, 
52.7% UC). In CD patients with ileal (31.7% vs 20%) and colonic (29.9% vs 25%) disease location folate deficiency was significantly higher than 
in patients with ileocolonic CD or upper GI involvement. In CD patients, vitamin B12 deficiency was associated with the onset of stenosis and 
intestinal surgery (42.9% vs 32.8% and 46% vs 33% for patients with versus without B12 deficiency).
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Conclusion: Our data indicate that due to frequent occurrence of deficiency states, regular monitoring and substitution of vitamins and iron are 
mandatory and may prevent long-term intestinal and extraintestinal complications in IBD patients.
Key Words:  anemia, ferritin, iron deficiency, folate acid, vitamin B12, inflammatory bowel disease, Crohn`s disease, ulcerative colitis, vitamins 
and trace element
INTRODUCTION
Vitamins act as cofactors and coenzymes and are required 
intermediaries in physiologic human metabolism. They are 
micronutrient chemical compounds that, with the exception of 
cholecalciferol, the human body is not able to synthesize. In 
addition, some specific vitamins, eg, vitamin D or vitamin A, 
have been reported to exert anti-inflammatory and/or immu-
nomodulatory effects.1 In inflammatory bowel disease(IBD) 
patients, vitamin deficiencies are often due to malnutrition 
or malabsorption (due to inflamed, malfunctioning mucosa 
and diarrhea or specific diet changes),2 which often results in 
anemia and negatively impacts quality of life.1, 3–5
Iron plays an important role in the long-term manage-
ment of IBD patients. A systematic review reported an overall 
prevalence of anemia occurring in 24% of IBD patients , in par-
ticular 27% in patients with CD and 21% in patients with UC.6 
Iron deficiency and chronic disease are the most important 
causes of anemia in IBD patients.7, 8 Other types of anemia, 
such as vitamin B12 megaloblastic anemia, accounts only for 
1.5% of all anemia in IBD patients.9 However, vitamin B12 and 
folic acid deficiency are common in IBD patients and supple-
mentation of those vitamins represents best standard of care.10 
Because ileal location of CD or ileocecal resections may lead to 
vitamin B12 malabsorption, it is anticipated that patients with 
CD are at greater risk for deficiency.11–14 Other less frequent 
causes of vitamin B12 deficiency may be fistulas, small intes-
tinal bacterial overgrowth (SIBO), reduced alimentary intake, 
increased physiologic requirements, protein losing enteropathy, 
and hepatic dysfunction.15, 16 Folate deficiency is common in 
IBD patients and often linked to sulfasalazine and/or metho-
trexate (MTX) therapy.12, 17, 18 Therefore, annually folate level 
measurement is recommended in these patients.19
An important preventive measure in the management 
of IBD patients is to provide proper nutrition (especially a 
fiber- rich diet), that may play a role in maintaining remission 
in those patients.20 The selection of a proper therapy, such as 
biological therapy, which is used with increasing frequency, 
seems not only to mitigate the inflammatory process in the gas-
trointestinal (GI) tract, but also to provide beneficial effects on 
the nutritional status of patients with CD, thus denoting the 
increasing importance of medications in vitamins and micro-
nutrient levels.21
Taken together current evidence suggests that vitamins 
might play an important role for the disease course and out-
come of IBD patients. It is of great importance to gain a deeper 
understanding about vitamin and iron status via regular nutri-
tional monitoring in IBD patients. In this report, using the 
well-characterized patient collective of the Swiss IBD Cohort 
Study (SIBDCS), we analyzed the frequency of complications 
and the association of specific patient characteristics, such 
as body mass index (BMI) or smoking status, in relation to 
iron-deficiency anemia and vitamin B12 and folate deficiency. 
This will help to identify a link between the lack of iron and/
or vitamins and possible consequences on disease outcome that 
might provide the base for an optimized patient care.
METHODS
Patient Data
Data were retrieved from the nationwide SIBDCS. 
The SIBDCS is a multicenter prospective observational 
population-based study and includes patients with IBD 
from Switzerland. The study was extended to all regions of 
Switzerland in 2006 in a multidisciplinary effort by gastroen-
terologists, pathologists, psychologists, and bioinformatics 
specialists. The cohort study is funded by ongoing support of 
the Swiss National Science Foundation. For inclusion in the 
SIBDCS, all patients must have a diagnosis established at least 
4  months before inclusion. Data are prospectively collected 
once a year and entered into a central database.22
Study Design
Using the exclusive patient collective of the SIBDCS, 
we evaluated iron, hemoglobin, ferritin, folic acid, and vita-
min B12 levels in IBD patients and assessed potential associ-
ations with specific diseases characteristics. All patients of the 
SIBDCS were included in the initial data analysis. Univariate 
and multivariate logistic regression analyses were performed. 
We included all patients with CD, UC, and indeterminate 
colitis (IC) available in the cohort for our study. The follow-
ing possible explanatory variables were considered. First, epi-
demiological characteristics were considered: diagnosis of CD, 
UC, or IC, age; disease duration (years); gender; age at diag-
nosis; BMI; and smoking status. Patients with CD were con-
sidered as a single entity and patients with Crohn’s colitis and 
Crohn’s ileitis were not distinguished. Second, disease charac-
teristics were reviewed: activity index; initial and current dis-
ease location; extraintestinal manifestations (EIM); existence 
of stenosis, fistula, fissure, and abscess; and intestinal surgery. 
Third, selected medications were considered: 5-ASA, VSL#3, 
E.  coli Nissle 1917, antibiotics, steroids, immunomodulators 
(azathioprine, 6-mercaptopurin), methotrexate, and anti-TNF 
antibodies. Complications included colorectal cancer (CRC), 
colonic dysplasia, osteoporosis/osteopenia, deep venous throm-
bosis, pulmonary embolism, gallstones, nephrolithiasis, mas-
sive hemorraghe, perforation/peritonitis, and growth failure. 
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Malabsorption syndrome, defined as failure of the GI tract to 
absorb 1 or more substances from the diet, also was determined 
as a complication. As supplementation therapy, we considered 
the consumption of magnesium, calcium, folate, iron, lactase, 
potassium, fish oil, multivitamin preparations, vitamin D, vita-
min E, vitamin B12, and bioflorin. To assess disease activity 
and allow comparison between UC (Modified Truelove and 
Witts activity index, MTWAI) and CD (Crohn’s disease activ-
ity index, CDAI), disease activity measures were normalized to 
a value between 0 and 100 and expressed as an activity index. In 
particular, IBD medication and supplementation therapy was 
documented by the treating physician in the specific SIBDCS 
questionnaires at patient inclusion and follow-ups and by the 
patient questionnaires.
Definitions of Anemia and Vitamin Deficiency
We analyzed the prevalence of vitamin and iron defi-
ciency, the need for supplementation therapy, and the incidence 
of anemia using the patient collective of the SIBDCS. A total 
of 2666 patients were included in the study, 1558 CD patients 
and 1108 UC patients. Vitamin B12 deficiency was defined 
as a vitamin B12 serum level below 180  ng/l; the cutoff  for 
folate deficiency was defined as a serum level below 4 ng/mL 
(9.064 nmol/l).
Anemia was defined as hemoglobin concentration (Hb) 
<= 12g/dl for nonpregnant women and <= 13  g/dl for men 
according to the World Health Organization definition. Iron-
deficiency anemia was defined by a ferritin level < 30 μg/l in 
patients without clinical, endoscopic, or biochemical evidence 
of active disease, according to the 2015 European Crohn´s and 
Colitis Organisation (ECCO) guidelines.19 Since ferritin meas-
urements are affected by disease activity, which is defined by 
CDAI for CD patients and Colitis activity index (CAI) for UC 
patients and C reactive protein (CRP) values, a serum ferritin 
up to 100 µg/L may still be consistent with iron deficiency.19 
According to the 2015 ECCO guidelines, in the presence of 
inflammation, the diagnostic criteria for anemia of chronic dis-
ease would be a serum ferritin > 100 µg/L and a transferrin 
saturation (TfS) < 20 %.19 However, since transferrin satura-
tion is only very incompletely documented in the SIBDCS, we 
decided to use the following definitions that already have been 
published using SIBDCS data: ferritin level between 30 and 100 
ug/l together with CDAI >= 150 or CAI >= 6 was defined as 
iron-deficiency anemia in combination with anemia of chronic 
disease.23
Statistical Analysis
All statistical analyses have been carried out using the 
Stata Software (v. 14.2, StataCorp, College Station, TX, USA). 
Normal QQ-plots were used to assess gaussianity of continu-
ous data. Gaussian-distributed data were reported as mean, 
standard deviation, and range, whereas non-Gaussian data 
were presented as median, interquartile range, and range. 
Differences in means between 2 independent groups for 
Gaussian-distributed data were assessed using the Student’s t 
test. Differences in distribution locations between 2independent 
groups for non-Gaussian data were assessed using the Mann-
Whitney-Wilcoxon rank sum test. Categorical data were pre-
sented as raw frequencies and relative percentages. Differences 
in distributions for categorical data between 2 or more groups 
were assessed using the chi-square test, or the Fisher’s exact test 
in case of insufficient sample size. A P value <0.05 was consid-
ered for statistical significance. Multiple testing adjustment was 
done using the Bonferonni’s correction.
Ethical Considerations
The SIBDCS has been approved by the respective ethics 
committees in Switzerland (Ethics Committee of the Canton 
Zürch: EK-1316). All patients signed an informed consent and 
confirmed their participation in the cohort study at the time of 
enrollment and gave informed consent for data collection and 
analysis for research purposes. The current substudy has been 
evaluated and approved by the scientific board of SIBDCS.
RESULTS
Folate Deficiency in IBD Patients
Of the total patient collective, folate levels were available 
from 755 CD and 480 UC/IC patients. There were 695 out of 
755 (92 %) CD patients and 454 out of 480 (94.6 %) UC/IC 
patients who had a folate deficiency according to out definition. 
No significant difference in BMI was found between patients 
showing folate deficiency and those with normal folate levels. 
However, in both groups of IBD, patients with folate deficiency 
were more often smokers (Table 1, Supplementary Figs. 1‒ 2).
CD patients with ileal (31.7 % vs 20 %), only colonic (29.9 
% vs 25 %), and unknown disease location (2.9 % vs 1.6 %) 
showed a significantly higher rate of folate deficiency, whereas 
ileocolonic location or upper GI involvement was not associ-
ated with folate deficiency. Interestingly, CD patients without 
folate deficiency featured significantly more fistula and fistula/
abscess-related surgery (11.9 % vs 26.7 %, P = 0.001; 18.9 % 
vs 30.0 %, P = 0.037) than patients with folate deficiency. UC/
IC patients had no significantly higher prevalence of intestinal 
complications. In particular, CRC , colonic dysplasia, osteopo-
rosis/osteopenia, anemia, deep venous thrombosis, pulmonary 
embolism, gallstone, nephrolithiasis, malabsorption syndrome, 
massive hemorrhage, perforation/peritonitis, and growth fail-
ure were not more frequent in those patients (Table 1).
Surprisingly, CD patients without folate deficiency 
revealed a higher prevalence of osteoporosis/osteopenia (17.7 
% vs 36.7 %, P < 0.001) and malabsorption syndrome (3.9 % 
vs 11.7 %, P = 0.005). In UC patients, we did not detect a sig-
nificant association with any extraintestinal complication. CD 
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patients ever treated with anti-TNF antibodies (34.1 % vs 48.3 
%, P = 0.027), currently treated with antibiotics (4.3 % vs 13.3 
%, P = 0.002), or steroids (28.1 % vs 43.3 %, P = 0.013) had 
a lower rate of folate deficiency. For UC/IC patients no such 
differences were found between patients with or without folate 
deficiency. Further details are shown in Table 1. In both groups, 
we did not detect a significant difference with respect to supple-
mentation therapy.
Vitamin B12 Deficiency in IBD Patients
Vitamin B12 levels were documented for 914 CD and 
545 UC/IC patients in the SIBDCS database. Out of 914 CD 
patients, 163 (17.8 %) suffered from vitamin B12 deficiency. 
Older patients (median 42  years vs 38  years, P  =  0.027) and 
smokers (45.1 % vs 33.8 %, P = 0.007) had a higher incidence 
for a vitamin B12 deficiency. In the UC/IC group a total of 
545 patients were analyzed, of whom 45 (8.2 %) had a vitamin 
B12 deficiency. There was no significant association with age, 
BMI,and smoking status (Table 2, Supplementary Figures 3, 4).
Vitamin B12 deficiency was associated with a higher 
disease activity at enrollment according to CDAI (48 vs 35, 
P = 0.041) and more frequent complications, in particular ste-
nosis (42.9 % vs 32.8 %, P = 0.013) and intestinal surgery (46 
% in CD patients 33 %, P  =  0.002) in CD patients. For UC 
patients, no relationship between a specific disease location and 
vitamin B12 deficiency was detected (Table 2).
As shown in Table  2, nephrolithasis was significantly 
associated with vitamin B12 deficiency in CD patients (6.1 % 
vs 2.8 %, P = 0.033). Furthermore, CD patients with vitamin 
B12 deficiency significantly more often suffered from iron-de-
ficiency- related anemia (26.4 % vs 21.3 %, P  =  0.012). CD 
patients under current treatment with anti-TNF antibodies 
had a lower rate of vitamin B12 deficiency (29.6 % vs 21.5 %, 
P = 0.037). In contrast UC/IC patients under 5-ASA therapy 
showed a higher rate of vitamin B12 deficiency (82.2 % vs 67.8 
%, P = 0.045). Further details are listed in Table 2.
Anemia According to Hemoglobin Levels
We next analyzed our data as a prevalence of iron-defi-
ciency anemia in relation to patient’s hemoglobin level. There 
were 305 (19.6 %) CD patients and 239 (21.6 %) UC patients 
who were found to suffer from an iron-deficiency anemia 
according to our definition. In the CD group, 46.9 % male 
and 53.1 % female suffering from iron- deficiency anemia 
showed a significantly lower BMI (22.0  kg/m2 vs 23.2  kg/m2, 
P  <  0.001) and were more often nonsmokers (21% vs 16.5% 
smokers). UC patients (56.1 % male and 43.9 % female) with 
anemia had a significantly lower BMI (22.6 kg/m2 vs 23.9 kg/
m2, P  <  0.001). Smoking status had no influence on anemia 
(Table 3, Supplementary Figures 5,6.
In the CD group, the highest prevalence of iron-defi-
ciency anemia was detected among patients suffering from an 
ileocolonic disease, followed by ileal and colonic localization of 
the disease. CDAI score was definitely higher in patients suffer-
ing from iron-deficiency anemia (53 vs 34, P < 0.001). Intestinal 
stenosis (41.3 % vs 31.7 %, P  =  0.001) and fistula (17.1% vs 
11.1%, P  =  0.004) had a significantly higher rate in anemic 
patients. In the UC/IC group, patients with pancolitis showed 
a higher prevalence of iron- deficiency anemia, followed by 
patients with left-sided colitis and proctitis. Anemic patients 
showed a significantly higher MTWAI score than patients 
without anemia (4 vs 2, P < 0.001). No significant association 
with a higher need of surgery was found between anemic and 
non-anemic patients (Tables 3, 4).
In CD patients with iron-deficiency anemia, we found 
a higher prevalence of malabsorption syndrome (6.2 % vs 
3.5 %, P = 0.031) and more GI haemorrhage (2.6 % vs 0.7 %, 
P = 0.004). Furthermore, anemic patients suffered from a sig-
nificantly higher rate of disease complications, such as fistula 
(17.1 % vs 11.1 % P = 0.004) and stenoses (41.3 % vs 31.7 %, 
P = 0.001). Further details are depicted in Table 3. As shown 
in Table 4 UC/IC patients with iron-deficiency anemia suffered 
significantly more from deep venous thrombosis (5.9 % vs 1.5 
%, P < 0.001) and malabsorption syndrome (3.8 % vs 0.8 %, 
P  =  0.001). UC patients with iron-deficiency anemia showed 
a significantly higher rate of erythema nodosum occurrence 
when compared with UC patients without iron-deficiency 
anemia (6.3% vs 2.1%, P = 0.001).
CD patients with iron-deficiency anemia significantly 
more often received steroids (40 % vs 27 %, P < 0.001) and 
antibiotics (8.9 % vs 3.5 %, P < 0.001) compared to patients 
without anemia. UC/IC patients with iron-deficiency anemia 
also consumed significantly more often steroids (52.7 % vs 
28.8 %, P < 0.001), antibiotics (5.9 % vs 1.8 %, P = 0.001), 
and anti-TNF antibodies (17.2 % vs 11.9 %, P = 0.031). No 
significant difference was found for other medications, such 
as mesalazine and immunosuppressants, eg, azathioprine 
or 6-mercaptopurin, in both, the CD and the UC group 
(Tables 3 , 4).
Anemia According to Ferritin Levels in IBD 
Patients
We finally analyzed the prevalence of anemia in relation 
to the patient’s iron status in CD and UC patients (Tables 5, 6, 
Supplementary Figs. 7, 8). Out of 1011 CD patients, 263 (26 
%) had an anemia with a ferritin level < 30 μg/l. Patients with 
anemia had a lower BMI (21.9 kg/m2 vs 23.2 kg/m2, P < 0.001) 
and were younger by diagnosis and during enrollment. In UC/
IC group (Table 6) from a total of 713 patients, 220 (30.8 %) 
had an anemia with ferritin level < 30 μg/l. Anemic UC patients 
also had a lower BMI (22.8 kg/m2 vs 23.6 kg/m2, P < 0.001) and 
were younger than patients without anemia. Smoking status 
did not have a significant influence on iron-deficiency anemia in 
both the CD and the UC groups.
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Anemic patients in both groups had a more active dis-
ease with a higher CDAI and MTWAI score, respectively, in 
comparison to non-anaemic patients (CD patients: 48 vs 39, 
P = 0.013; UC/IC patients: 6 vs 2, P < 0.001). For further details, 
see Tables 5 and 6. Surgical procedures in UC/IC patients were 
more frequently among the non-anaemic group when com-
pared with anemic patients (3.7 % vs 0.9 %, P = 0.048).
CD patients with iron-deficiency anemia (as listed in 
Table 5) suffered significantly more often from uveitis/iritis (9.5 
% vs 5.5 %, P = 0.023) and erythema nodosum (9.1 % vs 4.6 %, 
P = 0.006). Whereas anemic UC/IC patients had a higher inci-
dence of arthritis (28.6 % vs 20.9 %, P = 0.024), iron anaemic CD 
patients significantly had more folate and vitamin B12 deficiency 
(folate deficiency P = 0.025, vitamin B12 deficiency P = 0.024).
TABLE 1: Folate Deficiency in Relation to Significant Patients Characteristics in Crohn’s Patients and UC Patients 
(n: Total Number of Patient for Each Group)
CD Only No Folate Deficiency (n = 60 patients) Folate Deficiency (n = 695 patients) P value
Smoking status at diagnosis
 Non-smoker 39 (66.1)  329 (48.4) 
 Smoker 20 (33.9) 351 (51.6) 0.009
Initial CD location
 L1 (ileal) 5 (8.3) 182 (26.2) 
 L2 (colonic) 11 (18.3) 151 (21.7) 
 L3 (ileocolonic) 35 (58.3) 301 (43.3)
 L4 (Upper GI only) 2 (3.3) 5 (0.7)
 Unknown/unclear 7 (11.7) 56 (8.1) 0.002
Current CD location
 L1 (ileal) 12 (20.0) 220 (31.7)
 L2 (colonic) 15 (25.0) 208 (29.9) 
 L3 (ileocolonic) 28 (46.7) 242 (34.8) 
 L4 (Upper GI only) 4 (6.7) 5 (0.7) 
 Unknown/unclear 1 (1.6) 20 (2.9) 0.003
Other Fistula 16 26.7) 83 (11.9) 0.001
Fistula/abscess surgery. 18 (30.0) 131 (18.9) 0.037
Therapy (Ever treated)
 Anti-TNF 29 (48.3) 237 (34.1) 0.027
Current Therapy
 Antibiotics 8 (13.3) 30 (4.3) 0.002
 Steroids 26 (43.3) 195 (28.1) 0.013
 Anti-TNF 22 (36.7) 172 (24.8) 0.043
Complications 
 None 20 (33.3) 409 (58.9) 
 Yes 40 (66.7) 286 (41.2) <0.001
  Osteoporosis/Osteopenia 22 (36.7) 123 (17.7) <0.001
  Anemia 26 (43.3) 126 (18.1) <0.001
  Malabsorption syndrome. 7 (11.7) 27 (3.9) 0.005
Supplementation therapy
 Calcium 27 (45.0) 194 (27.9) 0.005
 Potassium 4 (6.7) 9 (1.3) 0.015
 Vitamin D 26 (43.3) 167 (24.0) 0.001
UC/IC ONLY No Folate Deficiency (26 patients) Folate Deficient (454 patients) P-value
Smoking status at diagnosis
 Nonsmoker 25 (96.2)  353 (79.2) 
 Smoker 1 (3.8) 93 (20.9) 0.040
Complications
 Anemia 11 (42.3) 88 (19.4)  0.005
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TABLE 2: Vitamin B12 Deficiency in Relation to Significant Patients Characteristics (n: Total Number of Patient for 
Each Group)
CD Only
No Vitamin B12 Deficiency  
(n = 751 patients)
Vitamin B12 Deficiency  
(n = 163 patients) Pvalue
Age at enrollment (y) (median, IQR; range) 38, 27–51; 42, 30–55;
16–88 18–77 0.027
Smoking status at enrollment
 Nonsmoker 487 (66.2)  89 (54.9) 
 Smoker 249 (33.8) 73 (45.1) 0.007
Current CD location 
 L1 (ileal) 223 (29.7) 60 (36.8) 
 L2 (colonic) 241 (32.1) 29 (17.8) 
 L3 (ileocolonic) 257 (34.2) 66 (40.5) 
 L4 (Upper GI only) 11 (1.5) 1 (0.6) 
 Unknown/unclear 19 (2.5) 7 (4.3)  0.002
CDAI at enrollment (median, IQR; range) 35, 14–76; 48, 23–88; 
0–450 0–280 0.041
Stenosis 246 (32.8) 70 (42.9) 0.013
Intestinal surgery 248 (33.0) 75 (46.0) 0.002
Current Therapy
 Anti-TNF 222 (29.6) 35 (21.5)  0.037
Complications
 Pyoderma gang.  45 (6.0)  3 (1.8)  0.032
 Nephrolithiasis 21 (2.8)  10 (6.1)  0.033
Supplementation therapy
 Vitamin B12 155 (20.6) 55 (33.7)  <0.001
Anemia (iron)
 None 516 (76.4)  100 (67.6) 
 Iron with active IBD 15 (2.2) 9 (6.1) 
 Iron 144 (21.3) 39 (26.4) 0.012
UC/IC ONLY
No Vit B12 Deficiency  
(n = 500 patients)
Vit B12 Deficiency  
(n = 45 patients) P-value
Current Therapy 
 5-ASA 339 (67.8) 37 (82.2)  0.045
Complications
 None 333 (66.6) 34 (75.6) 
 Yes 167 (33.4) 11 (24.4)  0.220
  CRCr 3 (0.6) 0 (0.0) 1.000
  Colonic Dysplasia 6 (1.2) 0 (0.0) 1.000
  Osteoporosis/Osteopeni 61 (12.2) 4 (8.9) 0.636
  Anemia Deep Venous 100 (20.0) 7 (15.6) 0.472
  Thromb 16 (3.2) 0 (0.0) 0.385
  Pulmonary Embolism 9 (1.8) 0 (0.0) 1.000
  Gallstone 10 (2.0) 1 (2.2) 1.000
  Nephrolitiasis 14 (2.8) 1 (2.2) 1.000
  Malabsorption syndrome 9 (1.8) 1 (2.2) 0.581
  Massive Hemorrage 8 (1.6) 0 (0.0) 1.000
  Perforation/Peritonitis 3 (0.6) 0 (0.0) 1.000
  Growth failure 0 (0.0) 0 (0.0) -
Supplementation therapy
 Iron 84 (16.8) 13 (28.9)  0.042
 Vitamin B12 26 (5.2) 9 (20.0) <0.001
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In the CD group (Table  5), anemia was not associated 
with the use of any medication. In contrast UC/IC patients with 
iron-deficiency anemia more frequently used immunomodula-
tors (63.6 % vs 51.9 %, P = 0.004), anti-TNF antibodies (26.8 % 
vs 15 %, P < 0.001), and steroids (42.7 % vs 28.4 %, P < 0.001). 
In the CD group, patients suffering from anemia more often 
used supplementation therapies than patients without anemia, 
in particular supplementation of calcium (40.7 % vs 25.6 %), 
iron (26.6 % vs 11 %), potassium (2.6 % vs 0.6 %), and vitamin 
D (33.8 % vs 23.1 %). A  similar result was observed among 
UC patients in that calcium (41.8% vs 25.1%), iron (27.2% vs 
13.8%), and vitamin D (36% vs 22.8%) supplementation ther-
apy was more common among anemic patients (Tables 5 , 6).
DISCUSSION
In the present study we aimed at analyzing prevalence 
and consequences of  vitamin and iron deficiency in patients of 
the SIBDCS. In line with current literature data about healthy 
populations,24, 25 smoking was clearly associated with folate and 
vitamin B12 deficiency in our SIBDCS patient collective. This 
finding can be explained by the observation that smokers con-
sume less amounts of  foods that are rich in antioxidants and 
tend to prefer a dietary pattern that is rich in meat and alco-
hol.26–28 A recent meta-analysis by Burr et al showed that folic 
acid supplementation decreases the risk of  CRC in patients 
with IBD29 and those data were confirmed by another study 
monitoring homocysteine levels.30 Some studies have shown 
that CD itself  is a risk factor for folate deficiency, mainly 
because of  the ileal location of  the disease, with an overall 
prevalence between 0%–60 %.16, 31, 32 In our cohort, the overall 
prevalence of  vitamin B12 and folic acid deficiency was higher 
than in other studies, in particular from the US and Canada. 
This observation might be linked to the fact that our cohort 
is primarily part of  a tertiary referral center. On the other 
TABLE 3: Anemia (Defined by Low Hemoglobin Levels) in Relation to Significant Patients Characteristics (n: Total 
Number of Patient for Each Group)
CD Only No Anemia (Hb) (n = 1253 patients) With Anemia (Hb) (n = 305 patients) P value
BMI (median, IQR; range) 23.2, 20.8-26.2 22.0, 19.6-24.8
14.0-48.1 13.9-43.4 <0.001
Smoking status at enrollment
 Nonsmoker 770 (62.9)  210 (70.0) 
 Smoker 454 (37.1) 90 (30.0)  0.022
CDAI at enrollment (median, IQR; range) 34, 13-74 53, 26-101 
0-450 6-296 <0.001
Other Fistula 139 (11.1) 52 (17.1) 0.004
Stenosis 397 (31.7) 126 (41.3) 0.001
Therapy (Ever treated)
 Steroids 1007 (80.4)  267 (87.5)  0.004
Current Therapy
 Antibiotics 44 (3.5) 27 (8.9) <0.001
 Steroids 338 (27.0) 122 (40.0) <0.001
 Anti-TNF 432 (34.5) 87 (28.5) 0.048
Complications
 Yes 427 (34.1)  162 (53.1)  <0.001
  Anemia 156 (12.5) 110 (36.1) <0.001
  Malabsorption syndrome 44 (3.5) 19 (6.2) 0.031
  Massive Haemorrhage 9 (0.7) 8 (2.6) 0.004
Supplementation therapy
 Calcium 321 (25.6) 124 (40.7) <0.001
 Iron 138 (11.0) 81 (26.6) <0.001
 Potassium 7 (0.6) 8 (2.6) 0.001
 Vitamin D 289 (23.1) 103 (33.8) <0.001
Anemia (iron)
None 626 (77.3)  116 (61.1) 
 Iron with active IBD 25 (3.1) 6 (3.2) 
Iron 159 (19.6) 68 (35.8) <0.001
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TABLE 4: Anemia (Defined by Low Hemoglobin Levels) in Relation to Significant Patients Characteristics (n: Total 
Number of Patient for Each Group)
UC/IC Only 
No Anemia (Hb) 
(n = 869 patients)
With Anemia (Hb) 
(n = 239 patients) Pvalue
Disease duration (y) (median, IQR; range) 6, 2-13 5, 1-11
0-50 0-34 0.006
BMI (median, IQR; range) 23.9, 21.7-26.6 22.6, 20.6-25.1
16.7-48.8 15.1-38.0 <0.001
Initial UC/IC location
 Pancolitis 333 (38.7) 109 (45.8) 
 Left-sided colitis 287 (33.3) 73 (30.7) 
 Proctitis 167 (19.4) 30 (12.6) 
 Unknown/unclear 74 (8.6) 26 (10.9) 0.034
Current UC/IC location
 Pancolitis 349 (40.2) 133 (55.7) 
 Left-sided colitis 352 (40.5) 84 (35.2) 
 Proctitis 144 (16.6) 17 (7.1) 
 Unknown/unclear 24 (2.8) 5 (2.1) <0.001
MTWAI at enrollment (median, IQR; range) 2, 1-5 4, 2-8
0-19 0-16 <0.001
Therapy (Ever treated)
 Steroids 653 (75.1) 196 (82.0) 0.026
 Immunomodulators 483 (55.6) 150 (62.8) 0.047
 Anti-TNF 161 (18.5) 65 (27.2) 0.003
Current Therapy
 Antibiotics 16 (1.8) 14 (5.9) 0.001
 Steroids 250 (28.8) 126 (52.7) <0.001
 Anti-TNF 103 (11.9) 41 (17.2) 0.031
EIM
 Yes 27 (3.1) 15 (6.3) 0.001
  Arthritis/arthralgia 23 (2.7) 15 (6.3) 0.023
  Uveitis/Iritis 1 (0.4) 0.041
Complications
 None 633 (72.8)  120 (50.2)
 Yes 236 (27.2) 119 (49.8)  <0.001
  Osteoporosis/Osteopen. 99 (11.4) 43 (18.0) 0.007
  Anemia Deep Venous 117 (13.5) 88 (36.8) <0.001
  Thromb 13 (1.5) 14 (5.9) <0.001
  Malabsorption syndrome. 7 (0.8) 9 (3.8) 0.001
Supplementation therapy
 Calcium 218 (25.1) 100 (41.8) <0.001
 Iron 120 (13.8) 65 (27.2) <0.001
 Vitamin D 198 (22.8) 86 (36.0) <0.001
Anemia (iron)
 None 418 (73.9) 71 (51.1) 
 Iron with active IBD 55 (9.7) 22 (15.8) 
 Iron 93 (16.4) 46 (33.1)  <0.001
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hand, lower rates in US and Canadian studies can likely also 
be explained with local folic acid fortification practices, since 
fortification with folic acid is not routinely done to a compar-
able extent in Switzerland, as eg, in the US. Nevertheless, folic 
acid and vitamin B12 supplementation must be considered in 
IBD patients with folate deficiency, especially in UC patients 
who show a higher incidence of  CRC.33 Steroid therapy and 
anti-TNF treatment are associated with normal folate levels, 
possibly because of  their anti-inflammatory action on the 
intestinal mucosa, thus providing a better reabsorption at the 
intestinal level.34 A similar conclusion can be drawn for vita-
min B12, in particular because of  the closely related way of 
absorption and the strictly connected metabolic pathways.31 
Of  note, also CD patients with current antibiotic treatment 
significantly more often show normal folate levels. This might 
be explained by a better disease control in those patients (sim-
ilar to patients with steroid or anti-TNF therapy) than by the 
onset of  SIBO due to IBD surgeries, since intestinal surgery 
in patient’s history is not associated with higher folate levels 
and bacterial overgrowth (which would be reduced by typical 
antibiotics used in CD, eg, metronidazole) that would rather 
increase folate levels with concomitant decrease in vitamin 
B12 levels.
IBD patients with anemia have a significantly lower BMI 
than patients without anemia. This finding is in line with the lit-
erature: subjects with normal BMI showed normal hemoglobin 
levels and less tendency to develop anemia.35, 36 Of note, smok-
ing is clearly associated with folate and vitamin B12 deficiency 
in our SIBDCS patients. However, surprisingly, nonsmoking 
status is positively associated with anemia in CD patients. This 
might be due to the fact that smokers show in general a trend 
towards higher hemoglobin levels compared to nonsmokers, 
which t can be explained by the well-studied reactive hemoglo-
bine hyperproduction in smokers.37, 38 Based on this explanation 
we hypothesize that the anemia rate in smoking CD patients is 
affected by higher hemoglobin levels due to smokingthat finally 
results in our observation that smoking is, in contrast to non-
smoking, not associated with anemia. Anemia is more common 
TABLE 5: Iron-Deficiency Anemia in Relations to Patients Significant (P < 0.05) Characteristics (n: Total Number of 
Patient for Each Group)
CD Only No Anemia (Iron) (n = 748 patients) With Anemia (Iron) (n = 263 patients) P value
Gender
 Male 381 (50.9) 93 (35.4) 
 Female 367 (49.1) 170 (64.6)  <0.001
Age at diagnosis (y) (median, IQR; range) 27, 20-37 23, 18-32
1-81 5-78 <0.001
Age at enrollment (y)(median, IQR; range) 39, 28-52 33, 24-44
16-88 17-85 <0.001
BMI (median, IQR; range) 23.2, 20.8-26.3 21.9, 19.9-25.2
13.9-48.1 14.6-43.4 <0.001
CDAI at enrollment (median, IQR; range) 39, 17-76 48, 17-95
0-435 0-388 0.013
EIM
 None 443 (59.2) 149 (56.7) 
305 (40.8) 114 (43.4) 0.467
 Yes 238 (31.8) 84 (31.9) 0.971
41 (5.5) 25 (9.5) 0.023
7 (0.9) 5 (1.9) 0.214
  Arthritis/arthralgia 34 (4.6) 24 (9.1) 0.006
  Uveitis/Iritis 57 (7.6) 21 (8.0) 0.849
  Pyoderma gang. 38 (5.1) 9 (3.4) 0.272
3 (0.4) 1 (0.4) 1.000
  Erythema nodosum 26 (3.5) 5 (1.9) 0.203
Complications
 Yes 387 (38.4)  129 (49.0)  0.002
Folate deficiency 475 (90.8) 171 (96.1) 0.025
Anemia (Hb) 116 (15.6) 74 (28.7) <0.001
Vit B12 deficiency 100 (16.2) 48 (23.2) 0.024
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in CD patients suffering from intestinal stenosis and fistula.39 
The higher disease severity in anemic CD patients as demon-
strated by significantly higher levels of CDAI can be explained 
by the fact that anemia in general leads to symptoms such as 
fatigue, failure to thrive, etc. On the other hand, a higher disease 
activity is known to be associated with anemia, as previously 
reported in the literature for CD patients.40, 41 Malabsorption 
syndrome and massive hemorrhage were more common in 
anemic CD patients. This finding can be explained as one of 
the causes of anemia might be malabsorption of iron from the 
intestine and loss of blood. Nevertheless, it is difficult to assess 
whether the primary cause of anemia in those patients is blood 
loss from the GI tract or the reduced absorption of iron.
A very interesting finding of  our study was the observa-
tion that UC patients ever treated with anti-TNF antibodies 
showed a lower tendency to develop anemia. This observation 
may be linked to the finding that chronic inflammatory anemia 
is supported by inflammatory cytokines, particularly TNF that 
affects iron metabolism.42, 43 The same observation was made 
for treatment with steroids that also act as anti-inflammatory 
drugs and repress cytokine formation (thus repressing anemia 
of  chronic disease). There are divergent opinions regarding the 
effect of  anti-TNF antibodies on anemia of  chronic disease, 
especially in IBD. Whereas a recent study from Koutroubakis 
et al showed no improvement of  anemia after 1 year of  treat-
ment,44 Bergamaschi et  al found a significant improvement 
of  hemoglobin levels.40 To date, there are many controversies 
about anti-TNF treatment and anemia resolution, and thus 
further studies are necessary to assess this issue in more detail. 
In the UC group, anemia quantified as ferritin levels showed 
an improvement under immunomodulatory therapy. Of note, 
about 60 % of IBD patients do not tolerate the oral form 
of iron substitution.45 If  the anemia is severe (<10 g/L) or if  
there are factors that indicate a complicated disease course, 
TABLE 6: Iron-Deficiency Anemia in Relation to Significant Patients Characteristics (n: Total Number of Patient for 
Each Group)
UC/IC Only
No Anemia (Iron) 
(n = 493 patients)
With Anemia (Iron) 
(n = 220 patients)
P 
value
Age at diagnosis (y) (median, IQR; range) 32, 24-41 27, 21-36
10-82 9-71 <0.001
Age at enrollment (y) (median, IQR; range) 41, 31-52 36, 27-44
17-84 15-73 <0.001
BMI (median, IQR; range) 23.6, 21-3-26.3 22.8, 20.7-25.3
15.1-48.8 16.7-38.4 0.014
Initial UC/IC location
 Pancolitis 191 (39.0) 91 (41.7)
 Left-sided colitis 153 (31.2) 82 (37.6)
 Proctitis 102 (20.8) 25 (11.5)
 Unknown/unclear 44 (9.0) 20 (9.2) 0.023
MTWAI at enrolment (median, IQR; range) 2, 1-4 6, 2-9
0-19 0-15 <0.001
Intestinal surgery 24 (4.9) 21 (9.6) 0.018
Therapy (Ever treated)
 Anti-TNF 74 (15.0) 59 (26.8) <0.001
 Immunomodulators 256 (51.9) 140 (63.6) 0.004
Current Therapy Steroids 140 (28.4) 94 (42.7) <0.001
EIM
 Yes  103 (20.9)  63 (28.6)  0.024
 Erythema nod. 18 (3.7) 2 (0.9) 0.048
Complications
 Yes  142 (28.8)  86 (39.1)  0.007
 Anemia 78 (15.8) 59 (26.8) 0.001
Supplementation therapy
 Iron 71 (14.4) 62 (28.2) <0.001
 Mutaflor 18 (3.7) 19 (8.6) 0.006
Anemia (Hb) 71 (14.5) 68 (31.5) <0.001
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intravenous iron substitution should be definitely taken into 
account.19, 46
Furthermore, we observed that anemic patients are likely 
to exhibit micronutrient deficiency. This should prompt the 
treating physicians to carefully check other micronutrient lab-
oratory values, when anemia is diagnosed. Patients suffering 
from anemia tend to have multiple supplementation therapies 
(calcium, potassium, and vitamin D) besides iron supplemen-
tation. This can be observed when analyzing CD and UC 
patients. Unfortunately, to date supplementation therapy in 
IBD patients is not a common practice in daily patient care. 
However, t because inflammation and common disease compli-
cations, such as strictures or intestinal surgery, lead to a loss of 
important gut segments,2, 47 deficiencies of micronutrients, vita-
mins, and minerals are a common problem in IBD patients.48 
Therefore, vitamin and iron levels should be regularly moni-
tored and deficiencies need to be treated to prevent complica-
tions and to improve the disease course. A further important 
preventive measure in the management of IBD patients is 
providing a fiber-rich diet that may play a role in maintaining 
remission in those patients, reducing the risk of a more severe 
disease course, and CRC development. Indeed, a high dietary 
fiber intake has even been shown to be negatively associated 
with the risk of developing CD (but not UC) in a very large 
prospective study from the US.49 As possible mode of actions, 
it is hypothesized that dietary fibers directly interact with the 
intestinal microbiome, eg, by modulating intestinal immune 
responses or by directly affecting intestinal microbiota com-
position.20 Therefore, based on the literature, a fiber-rich diet 
seems to have beneficial effects for IBD patients and should be 
promoted by the treating physicians.
In the Filmann et al study 2192 patients from all across 
Europe were included.6 In contrast, our study seems herein to 
be superior in a way that we were able to include 2666 IBD 
patients alone from Switzerland. The overall prevalence of 
anemia in IBD patients in the Filman study was 24 %, being 57 
% of those patients were iron deficient. In our study, iron-defi-
ciency anemia was detected in 19.6 % of CD patients and 21.6 
% of UC patients. This suggests that iron-deficiency anemia 
might be a little bit more frequent than compared to the whole 
of Europe. However, this observation might be related to the 
clear strength of our study: we present data of a large and 
very well-characterized patient collective that has been treated 
according to comparable guidelines. In contrast, the European 
collective, put together based on a literature search, represents 
patients from a broad number of countries who have most 
likely been treated according to different guidelines that makes 
data interpretation difficult. It might be that iron substitution 
is started according to very different guidelines in different 
European countries that might critically affect comparability of 
the data. Therefore, our study represents a large and in the end 
likely homogeneously treated patient collective that adds crit-
ical value to the obtained findings. As a result our data might 
contribute to daily clinical practice, since these findings suggest 
that regular monitoring and substitution of vitamins and iron 
should be mandatory and may prevent long-term intestinal and 
extraintestinal complications in IBD patients.
CONCLUSIONS
In summary, our data support that folate, vitamin B12, 
and iron levels in patients suffering from IBD regardless of the 
subtype should be monitored routinely. In the case of vitamin 
deficiency, a substitution therapy needs to be established, thus 
preventing a complicated disease course. Furthermore, future 
investigations are needed to assess a possible link between cur-
rent long-term medical treatment and/or nutrient deficiencies 
to optimize patient care.
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Supplementary data are available at Inflammatory Bowel 
Diseases online.
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